Italy tests osteoporosis drug to treat Covid-19
Using supercomputer models and a chemical library of 500-billion molecules, raloxifene is being used in trials of 450 patients
27 October 2020 - 11:42
Milan — Italy’s main medicines regulator gave the go-ahead on Tuesday for human clinical trials on raloxifene, a generic osteoporosis drug that researchers hope may also help reduce Covid-19 symptoms and make patients less infectious.
The drug was identified as a potential Covid-19 treatment by researchers using supercomputers to screen more than 400,000 molecules for chemical characteristics that might inhibit the virus, focusing on those already approved for use in humans...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.